Aerovate Therapeutics (AVTE) Competitors $2.56 -0.07 (-2.66%) (As of 04:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVTE vs. CTMX, IMUX, MGTA, GOSS, MRSN, LYEL, BTMD, RZLT, ZURA, and BMEAShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include CytomX Therapeutics (CTMX), Immunic (IMUX), Magenta Therapeutics (MGTA), Gossamer Bio (GOSS), Mersana Therapeutics (MRSN), Lyell Immunopharma (LYEL), biote (BTMD), Rezolute (RZLT), Zura Bio (ZURA), and Biomea Fusion (BMEA). These companies are all part of the "medical" sector. Aerovate Therapeutics vs. CytomX Therapeutics Immunic Magenta Therapeutics Gossamer Bio Mersana Therapeutics Lyell Immunopharma biote Rezolute Zura Bio Biomea Fusion CytomX Therapeutics (NASDAQ:CTMX) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Does the MarketBeat Community believe in CTMX or AVTE? CytomX Therapeutics received 353 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 65.49% of users gave CytomX Therapeutics an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformCytomX TherapeuticsOutperform Votes37265.49% Underperform Votes19634.51% Aerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% Do insiders and institutionals believe in CTMX or AVTE? 67.8% of CytomX Therapeutics shares are owned by institutional investors. 7.0% of CytomX Therapeutics shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate CTMX or AVTE? CytomX Therapeutics presently has a consensus price target of $5.77, suggesting a potential upside of 477.25%. Aerovate Therapeutics has a consensus price target of $2.25, suggesting a potential downside of 12.11%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe CytomX Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is CTMX or AVTE more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Aerovate Therapeutics' net margin of 0.00%. CytomX Therapeutics' return on equity of -41.47% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics10.96% -41.47% 8.11% Aerovate Therapeutics N/A -86.12%-73.38% Which has higher earnings & valuation, CTMX or AVTE? CytomX Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$119.57M0.65-$570K$0.175.88Aerovate TherapeuticsN/AN/A-$75.52M-$2.99-0.86 Which has more volatility and risk, CTMX or AVTE? CytomX Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500. Does the media prefer CTMX or AVTE? In the previous week, CytomX Therapeutics had 10 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 16 mentions for CytomX Therapeutics and 6 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.88 beat CytomX Therapeutics' score of 0.61 indicating that Aerovate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Aerovate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCytomX Therapeutics beats Aerovate Therapeutics on 15 of the 17 factors compared between the two stocks. Ad Porter & CompanyElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.91M$7.02B$5.35B$8.88BDividend YieldN/A8.03%4.98%4.04%P/E Ratio-0.8611.36132.0617.45Price / SalesN/A376.471,259.5098.78Price / CashN/A49.2239.0436.42Price / Book0.659.076.265.86Net Income-$75.52M$153.49M$118.56M$224.86M7 Day Performance-6.57%-2.21%-2.16%-0.94%1 Month Performance19.63%7.48%2.44%3.65%1 Year Performance-81.91%37.84%35.47%26.39% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate Therapeutics1.6263 of 5 stars$2.56-2.7%$2.25-12.1%-78.7%$73.91MN/A-0.8651Earnings ReportShort Interest ↓CTMXCytomX Therapeutics4.4719 of 5 stars$1.00flatN/A-17.9%$78.12M$101.21M7.14170Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionGap UpIMUXImmunic2.9196 of 5 stars$1.18flatN/A+20.7%$106.29MN/A-0.7970Analyst DowngradeInsider BuyingShort Interest ↑News CoverageHigh Trading VolumeMGTAMagenta TherapeuticsN/A$0.70-7.7%N/A+0.0%$42.44MN/A0.0067Gap DownGOSSGossamer Bio4.5044 of 5 stars$0.89flatN/A+29.5%$200.66M$95.84M-2.27180Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageMRSNMersana Therapeutics4.3421 of 5 stars$2.55+9.0%N/A+110.4%$312.83M$36.85M-2.93150News CoverageGap UpLYELLyell Immunopharma0.4821 of 5 stars$1.22-17.6%N/A-29.0%$312.32M$54,000.00-1.49270Earnings ReportAnalyst ForecastHigh Trading VolumeBTMDbiote3.8822 of 5 stars$5.65+1.1%N/A+38.8%$306.34M$185.36M33.24194Short Interest ↓Analyst RevisionNews CoverageRZLTRezolute4.3399 of 5 stars$5.72-1.5%N/A+561.2%$304.25MN/A-4.3040Positive NewsZURAZura Bio3.9777 of 5 stars$4.47+4.0%N/A+9.5%$300.43MN/A0.003Earnings ReportAnalyst ForecastAnalyst RevisionBMEABiomea Fusion3.7393 of 5 stars$8.18-7.9%N/A-15.2%$296.44MN/A-2.0450 Related Companies and Tools Related Companies CytomX Therapeutics Competitors Immunic Competitors Magenta Therapeutics Competitors Gossamer Bio Competitors Mersana Therapeutics Competitors Lyell Immunopharma Competitors biote Competitors Rezolute Competitors Zura Bio Competitors Biomea Fusion Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTE) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you wa...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
